Introduction
Tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) were recently approved by the FDA for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. This is the culmination of at least 25 years of work on chimeric antigen receptor (CAR) T cells. CAR T cells are T cells that have been genetically engineered to express a CAR, which recognizes a disease-specific extracellular epitope and induces a cytotoxic T lymphocyte response. The dramatic success of CAR T cell therapy for certain cancers ushers in an entirely new category of living cell-based therapeutics. Attempts to use CAR T cell therapy to treat HIV have also been pursued for at least the last 25 years. This review focuses on anti-HIV CAR T cells and evaluates the current status of anti-HIV CAR T cell therapy. Various other strategies to use T cell therapy to treat HIV have been explored, including infusion of HIV-specific T cells, delivery of autologous T cells engineered to be HIV-resistant, and cells genetically engineered to express HIV-specific T cell receptors, which have been reviewed by others [1] . The use of anti-HIV CAR NK cells is also being explored [2, 3] , but is beyond the scope of this review. This review focuses specifically on strategies and attempts to use CAR T cells to target HIV.
Need for Novel Anti-HIV Therapies
More than 30 million people are infected with HIV [4] , and HIV remains the fifth leading cause of disability-adjusted lifeyears worldwide [5] . ART dramatically decreases mortality [6] , but there are side effects, long-term toxicities, expense, stigma, and inconvenience associated with chronic treatment, and HIV-infected individuals on ART have an increased risk of malignancies [7] , cardiovascular disease [8] , neurologic disease [9] , and shortened life expectancy [10] . In addition, another 30% of people living with HIV/AIDS in the USA are in care but do not have an undetectable viral load [11] . Therefore, a cure for HIV remains an important treatment goal.
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Background on Adoptive Transfer of Autologous CAR T Cells CAR are genetically engineered T cell receptors that usually include an extracellular single-chain variable fragment derived from an antibody that targets an epitope on the surface of cancerous cells, linked to the intracellular domain of the T cell receptor (CD3ζ) [12] [13] [14] [15] [16] [17] . In most therapeutic applications, CAR are transduced into donor lymphocytes and expanded ex vivo before being transfused back into the patient. They are designed to redirect T cells to target cells that express specific cell-surface epitopes. CAR T cells function by inducing a MHC-independent cytotoxic T lymphocyte response. CAR T cells have recently shown dramatic clinical benefit (67% 6-month survival for relapsed/refractory leukemia compared with < 25% with best available chemotherapy [18] ), and the efficacy of the CAR T cells has persisted for > 6 months in the majority of participants that did not undergo stem cell transplantation [18] [19] [20] [21] [22] .
Potential Advantages of CAR T Cells to Target Residually Active HIV-Infected Cells
Anti-HIV CAR are appealing for at least three reasons: (1) CAR T cells are MCH independent and can therefore target HIV-infected cells that are not effectively cleared by the host's endogenous CTLs (because HIV variants evolve to escape restriction by host CTL [23] [24] [25] , HIV nef downregulates MHC-I expression [26] [27] [28] , immune exhaustion [29, 30] , or immune tolerance [31, 32] ). (2) CAR T cells can retain cytotoxic activity for at least 6 months [18, 33, 34] and CAR DNA has been detectable in the peripheral blood for up to 10 years [35] , potentially providing prolonged therapeutic benefit by targeting both the actively HIV-expressing cells and cells that reactivate in the future. (3) CAR T cells have also been found to traffic to the CNS [21] , a potentially important reservoir of HIV that is difficult to treat with traditional pharmacologic agents.
First-Generation Anti-HIV CAR T Cells
"First-generation" CAR included an extracellular scFv (single-chain variable fragments) derived from an antibody that targets an epitope on the surface of cancerous cells, linked to the intracellular domain of the T cell receptor (CD3ζ) [12] [13] [14] [15] [16] [17] . First-generation anti-HIV CAR have been reviewed [36] [37] [38] and most of the published studies [39] [40] [41] [42] [43] [44] [45] [46] [47] are summarized in Table 1 . Over the course of 25 years, many different anti-HIV CAR designs have been explored, and some of the important variables are apparent in Table 1 . The epitope targeted by a CAR is thought to be critical. Two general approaches to targeting HIV have been pursued. The most established approach is to use CD4 to target HIV Env-expressing cells. CD4 is the natural ligand for HIV, and HIV must bind to CD4 in order to replicate, therefore using CD4 as the targeting ligand should have high binding affinity for all HIV Env variants with minimal chance of viral escape. However, using CD4 has some potential disadvantages. For example, it may be difficult for CD4-based CAR T cells to outcompete for HIV binding in the presence of large numbers of native CD4+ cells that express high levels of CD4. Another potential concern with using CD4 as the ligand for a CAR T cell is that there could be off target toxicity for cells that express high levels of MHC class II, although the studies that have looked for this potential complication [39, 40, 46] have not seen a problem in vitro. Another concern with a CD4-based CAR is that expressing CD4 on CD8+ CAR T cells will allow efficient HIV infection of CD8+ CAR T cells [47, 48] . To avoid this problem, several groups have developed strategies to prevent HIV infection of CD4-based CAR T cells [47] [48] [49] [50] , although engineering HIV-resistant CAR T cells is more complex and likely to be less efficient.
An alternative strategy for targeting HIV Env-expressing cells is to use anti-HIV antibodies as the binding domain for HIV-infected cells. This avoids some of the concerns regarding using CD4, but the binding affinity, breadth, and immunogenicity of the antibodies are potentially problematic. To target all HIV variants and to prevent HIV escape, Ab-based CAR will likely need to incorporate binding domains from multiple monoclonal antibodies. Fortunately, the number, breadth, and potency of available anti-HIV antibodies have improved dramatically in recent years. Combining CAR based on multiple broadly neutralizing antibodies administered in the presence of ART (initially) should reduce the risk of viral escape, although it adds complexity and likely decreases efficiency of CAT T cell production.
Looking at Table 1 , it is also possible to identify aspects of anti-HIV CAR T cells that have not been fully optimized. Several studies suggest that the distance between the targeting domain of the CAR and the transmembrane domain influences CAR function, although the optimal spacer distance has not been established for most CAR constructs. Different groups have begun to consider the CAR T cell phenotype. The biggest issue seems to be whether CD4+ CAR T cells are necessary or whether CD8+ CAR T cells alone are sufficient for treatment, but the specific phenotype of the CD8 and CD4 CAR T cells also has potential to be important and has not been explored yet for anti-HIV CAR T cells. In addition, it is clear from Table 1 that these constructs have been tested in a wide range of different assays, and very few of the firstgeneration constructs have been tested in vivo. 
Clinical Testing of First-Generation Anti-HIV CAR
Despite limited in vivo efficacy data, four clinical trials of first-generation CAR T cells were performed (see Table 2 ) [51] [52] [53] . These were some of the first clinical trials of CAR T cells, and the study by Deeks et al. may be the only randomized control trial of CAR T cells. All of these studies used the CD4-based CAR, but were designed quite differently. The collective published results convincingly show that it is possible to engineer T cells from HIV-infected individuals, and that the engineered T cells survive in vivo. None of the recipients received immunoconditioning, although some of these studies were done in conjunction with IL-2 treatment. In the long-term follow-up study, in which the participants were followed for at least 10 years, the CAR DNA was detectable in almost all participants [35] . Reassuringly, no significant short-or long-term adverse side effects were identified. However, despite the persistence of the CAR T cells, there was not a statistical impact on the main viral outcome, the number of viral blips while on ART, or the amount of HIV RNA or DNA in the peripheral blood. One notable exception was the study by Deeks et al., in which anti-HIV CAR treatment reduced the infectious units per million PBMC (IUPM) by about 50% (p = 0.02) at 24 weeks, compared to control participants who received an autologous T cell infusion that had not been transduced with an anti-HIV CAR. Although this was not a primary endpoint of the study, IUPM is a presumptive gold standard measure of the viral reservoir, which suggests there was some in vivo efficacy. Despite the favorable safety profile and the hint of efficacy, no further clinical trials of anti-HIV CAR have been conducted. 
Second-Generation Anti-HIV CAR T Cells
First-generation CAR T cells were also relatively ineffective for cancer. However, when co-stimulatory domains were added to anti-cancer CAR constructs, there were dramatic improvements in clinical efficacy, as measured by both remission and survival rates [18] [19] [20] [21] [22] . Second-generation CAR include intracellular co-stimulatory domains (usually CD28 or 4-1BB), which are important for lymphocyte activation and persistence [13, 14, 16, 54] . Adoptive transfer of autologous lymphocytes genetically engineered with second-generation CAR has shown dramatic clinical benefit (67% 6-month survival for relapsed/refractory leukemia compared with < 25% with best available chemotherapy [18] ), and the efficacy of the CAR T cells has persisted for > 6 months in the majority of participants that did not undergo stem cell transplantation [18] [19] [20] [21] [22] . Based on the success of second-generation CAR T cells for CD19+ malignancies, several groups have developed second-generation anti-HIV CAR T cells, which are summarized in Table 3 [1, 48-50, 55, 56] . Remarkably, almost all of the reported second-generation CAR T cells seem to be functional. First-and second-generation anti-HIV CAR T cells were not compared in most studies, but based on the experience with cancer, there is an assumption that secondgeneration CAR T cells will outperform first-generation CAR T cells in vivo. The one report that directly compared first-and second-generation CAR showed that including costimulatory domains can reduce the percentage of HIVinfected (gag+) cells in co-culture, but there was significant variability based on which co-stimulatory domain was included [1] . As with first-generation anti-HIV CAR, groups are pursuing strategies using CD4 or BNAbs as the binding ligand for Env-expressing cells. However, very few of these constructs have been tested or compared in in vivo models and none have been testing in an in vivo model of latent infection, which is the setting were anti-HIV CAR T cells would be most likely to be used.
Conclusions
Next Steps for Anti-HIV CAR Repeated success in in vitro experiments, and the recent success of second-generation CAR for malignancies, suggests that the development of anti-HIV CAR should continue. There continues to be some debate about whether CD4 or MAbs are better targeting ligands for the CAR, which costimulatory domains to include, whether CD4+ anti-HIV CAR T cells are needed, and whether anti-HIV CAR T cells need to be protected from HIV infection. One challenge in comparing these strategies is that all the studies have used different assays to evaluate HIV CAR T cell efficacy. In addition, with a genetically engineered cell therapy, there are vastly more variables to the product than with a traditional therapeutic. For example, cell dose, cell viability, the mix of cellular phenotypes, CAR expression, and CAR copy number are all likely to influence CAR T cell engraftment, persistence, and trafficking, and presumably influence efficacy. It would be much easier for the field if there were well-established, standardized, in vitro assays that correlated with clinical efficacy, but until there is a clinical success, this is likely to remain elusive. Ideally, the most promising products would also be studied in an in vivo model of ART-induced HIV latency, since this is the likely goal of CAR T cell therapy. This is important because of decreased antigen burden during ART, and demonstrating the efficacy of CAR T cells in this setting is expected to be more difficult. However, studying CAR T cells in a ART-treated animal model such as HIV-infected humanized mice or primates is not trivial and can be very expensive, and the models may not recapitulate subtleties of HIV infection in humans. The humanized mouse model has the potential to be relatively high throughput, but it is a relatively artificial system, and the mice cannot be very followed for very long. The primate model is more physiologic, but many of the human protein domains may be immunogenic in primates. Because of limitations with the available animal models and because the CD4 CAR has already been tested in humans, some groups are moving directly toward clinical trials. Hopefully, a combination of CAR T cell data from HIVinfected humanized mice and primates, as well as more pilot human data will move the field forward. There continues to be optimism that there is an opportunity to leverage the success and technological advances of CAR T cell therapy for cancer and apply it to HIV.
